Management of cancer-associated venous thrombosis

Vascular Health and Risk Management

Volumn 2, Issue 4, 2006, Pages 351-356

  Er, Ozlem ^a   Zacharski, Leo ^b  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Cancer; Dalteparin; Low molecular weight heparin; Venous thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ANTIVITAMIN K; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; TAMOXIFEN; TINZAPARIN; WARFARIN;

ABDOMINAL CANCER; ANTINEOPLASTIC ACTIVITY; ARTERY THROMBOSIS; BLEEDING; BREAST CANCER; BREAST METASTASIS; CANCER; CANCER SURGERY; CANCER SURVIVAL; CATHETER THROMBOSIS; CENTRAL VENOUS CATHETERIZATION; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENDOTHELIUM LESION; HEPARIN INDUCED THROMBOCYTOPENIA; HORMONAL THERAPY; HUMAN; IMMOBILIZATION; LOW DRUG DOSE; LUNG EMBOLISM; LUNG SMALL CELL CANCER; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; PHLEBOGRAPHY; POSTOPERATIVE THROMBOSIS; REVIEW; RISK FACTOR; TREATMENT CONTRAINDICATION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; RECURRENCE; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 33846922610     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: 10.2147/vhrm.2006.2.4.351     Document Type: Review

References (40)

1. Alcalay A, Wun T, Khatri V, et al. 2006. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol, 24:1112-18.
2. Altinbas M, Cuskun HS, Er O, et al. 2004. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost, 2:1266-71.
3. Balestreri L, De Cicco M, Matovic M, et al. 1995. Central venous catheter-related thrombosis in clinically asymptomatic oncologic patients: a phlebographic study. Eur J Radiol, 20:108-11.
4. Bergqvist D, Burmark U, Flordal P, et al. 1995. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis:2500 versus 5000 XaI units in 2070 patients. Br J Surg, 82:496-501.
5. Bergqvist D, Agnelli G, Cohen A, et al. 2002. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med, 346:975-80.
6. Bern M, Lokich J, Wallach S, et al. 1990. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med, 112:423-8.
7. Bona R. 1999. Thrombotic complications of central venous catheters in cancer patients. Semin Thromb Hemost, 25:147-55.
8. Buller HR, Agnelli G, Hull RD, et al. 2004. Antitrombotic therapy for venous thromboembolic disease. Chest, 126:421S-428S.
9. Chew H, Wun T, Harvey D, et al. 2006. The incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med, 166:458-64.
10. Clagett GP, Reisch JS. 1988. Prevention of venous thromboembolism in general surgical patients. Ann Surg, 208:227-40.
11. Dolovich LR, Ginsberg JS, Douketis JD, et al. 2000. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism:examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med, 160:181-8.
12. Galster H, Kolb G, Kohsytorz A, et al. 2000. The pre-, peri-, and postsurgical activation of coagulation and the thromboembolic risk for different risk groups. Thromb Res, 100:381-8.
13. Geerts WH, Pineo GF, Heit JA, et al. 2004. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 126:338S-400S.
14. Gould MK, Dembitzer AD, Doyle RL, et al. 1999. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med, 130:800-9.
15. Heit JA, Silverstein MD, Mohr DN, et al. 1999. Predictors of survival after deep vein thrombosis and pulmonary embolism: A population based, cohort study. Arch Intern Med, 159:445-53.
16. Hettiarachchi RI, Lok J, Prins MH, et al. 1998. Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk factors, and diagnosis. Cancer, 83:180-5.
17. Hull RD, Pineo GF, Mah AF, et al; for the LITE Investigators. 2003. A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. J Thromb Haemost, 1(Suppl 1):OC395.
18. Kakkar AK, Levine MN, Kadziola Z, et al. 2004. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol, 22:1944-8.
19. Karthaus M, Kretzschmar A, Kroning H, et al. 2006. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol, 17:289-96.
20. Khorana AA. 2003. Malignancy, thrombosis and Trousseau: the case for an eponym. J Throm Haemost, 1:2463-5.
21. Klerk CPW, Smorenburg SM, Otten JMMB, et al. 2005. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol, 23:2130-5.
22. Lee AYY, Levine MN. 2002. Cancer and thrombosis: Current concepts in patient care. Connecticut: Chase Medical Communications.
23. Lee AY, Levine MN, Baker RI, et al. 2003. Low molecular weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med, 349:146-53.
24. Lee A, Rickles FR, Julian JA, et al. 2005. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol, 23:2123-9.
25. Levine M, Hirsh J, Gent M, et al. 1994. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet, 343:886-9.
26. Levitan N, Dowlati A, Remick SC, et al. 1999. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Med (Baltimore), 78:285-91.
27. Lip GY, Chin BS, Blann AD. 2002. Cancer and the prothrombotic state. Lancet Oncol, 3:27-34.
28. Meyer G, Marjanovic Z, Valcke J, et al. 2002. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med, 162:1729-35.
29. Michaels L. 1964. Cancer incidence and mortality in patients having anticoagulant therapy. Lancet, 22:832-5.
30. Mismetti P, Laporte S, Darmon JY, et al. 2001. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg, 88:913-30.
31. Monreal M, Alastrue A, Rull M, et al. 1996. Upper extremity deep venous thrombosis in cancer patients with venous access devices - prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost, 75:251-3.
32. Monreal M, Lensing AWA, Prins MH, et al. 2004. Screening for occult cancer in patients with acute deep vein thrombosis and pulmonary embolism. J Throm Haemost, 2:876-81.
33. Prandoni P, Lensing A, Piccioli A, et al. 2002. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood, 100:3484-8.
34. Rasmussen MS, Wille-Jorgensen P, Jorgensen LN, et al. 2003. Prolonged thromboprophylaxis with low molecular weight heparin (dalteparin) following major abdominal surgery for malignancy [abstract]. Blood, 102:186.
35. Saphner T, Tormey DC, Gray R. 1991. Venous and arterial thrombosis in patients who receive adjuvant therapy for breast cancer. J Clin Oncol, 9:286-94.
36. Sorensen HT, Mellemkjaer L, Olsen JH, et al: 2000. Prognosis of cancers associated with venous thromboembolism. N Engl J Med, 343:1846-50.
37. van den Belt AG, Prins MH, Lensing AW, et al. 2000. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev, CD001100.
38. Wolff R. 2003. Are patients with cancer receiving adequate thromboprophylaxis? Results from FRONTLINE. Cancer Treat Rev, 29(Suppl 2):7-9.
39. Zacharski LR, Henderson WG, Rickles FR, et al. 1981. Effect of warfarin on survival in small cell carcinoma of the lung. JAMA, 245:831-5.
40. Zacharski LR. 2003. Malignancy as a solid-phase coagulopathy: implications for the etiology, pathogenesis, and treatment of cancer. Semin Thromb Hemost, 29:239-46.